Drug discovery Archives

News and Trends 28 Nov 2022

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca. It is worth up to $402 million, for its NRF2 Activator program. AstraZeneca will develop and commercialize an oral therapy, C4XD. This is for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD). C4X Discovery will receive […]

November 28, 2022 - 3 minutesmins - By Liza Laws

Interview 18 Nov 2022

How cardioids can usher in the next generation of drug discovery

The California-based Molecular Devices brings automated 3D cell culture and image analysis together with HeartBeat.bio’s cardioid technology to enable unique and scalable drug discovery and cardiac safety testing. Cardiovascular diseases are the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. Despite this, the cardiovascular therapeutics market has lagged behind the […]

November 18, 2022 - 6 minutesmins - By Omnia Ibrahim

More News! 9 Nov 2022

Sensorium closes $30M deal to advance drug discovery engine

Sensorium Therapeutics, announced the closing of a $30 million series a financing to advance its initial asset, SENS-01, and Biodynamic Discovery Platform (BDP). The platform is a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as therapeutics. The round was led by Santé Ventures, a specialized healthcare and life sciences investment firm […]

November 9, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Nov 2022

Google and Meta AI could boost cancer research and drug discovery

Encoded in the DNA, a protein may be represented as a thread of hundreds of individual molecules called amino acids, linked together. Depending on the particular amino acids combination, a protein folds in a particular way, resulting in a functional 3D shape. The shape makes the function, and with 20 different amino acids available, the […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

More News! 4 Nov 2022

Optibrium and Lhasa Limited study published on predictive modelling for enzymes

A peer reviewed study published in the Journal of Medicinal Chemistry has been published by Optibrium and Lhasa Limited that shows advance predictive modelling for drug-metabolizing enzymes. The companies are two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and development. In the paper, ‘Predicting Regioselectivity of AO, CYP, […]

November 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 1 Nov 2022

First to market doesn’t guarantee success

A comparison of two cancer drugs, Opdivo and Keytruda, reveals that being the first-to-market is not necessarily the main factor in a drug’s success. For the first four years since their approval, the anticancer drug Opdivo outperformed Keytruda in sales. But this trend reversed in 2018, with Keytruda’s sales becoming higher than Opdivo’s. Recently, a […]

November 1, 2022 - 4 minutesmins - By Jim Cornall

More News! 31 Oct 2022

Drug discovery company signs exclusive license to use university’s technology

A drug discovery and development company using deubiquitylase (DUB) modulators as therapeutics for areas of high unmet needs has signed an exclusive license with the University of Southern Denmark for its UbiSite technology. Sheelagh Frame, is chief scientific officer, at Ubiquigent, the company that has signed the agreement. She said: “We are delighted to have […]

October 31, 2022 - 3 minutesmins - By Liza Laws

News and Trends 31 Oct 2022

PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets

U.K. biopharma company PhoreMost Ltd. has entered into a multi-target collaboration with Arvinas, a company active in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive research funding and will be eligible for pre-clinical, clinical, and commercial milestones. PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. […]

October 31, 2022 - 2 minutesmins - By Jim Cornall

longevity treatment bioAge Kristen Fortney

Interview 31 Oct 2022

AI and biobanks could open the way to longevity treatments

The development of longevity treatments is hampered by a lack of biomarkers and validated drug targets. BioAge’s co-founder and CEO, Kristen Fortney, explains how the firm is enlisting machine learning (ML), artificial intelligence (AI) and biobanks to fill in the gaps. The quest for human longevity treatments is attracting big cash in the biotech industry. […]

October 31, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 26 Oct 2022

Partnership between Paradigm4 and Alnylam accelerates drug target discovery

New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam. Paradigm4’s REVEAL integrative analytics platform enables extraordinary pace and productivity Alnylam Pharmaceuticals to access the targets for its therapeutics pipeline at a very fast pace. Using the cloud-based scientific analytics […]

October 26, 2022 - 3 minutesmins - By Liza Laws

cancer cell screening drug discovery microplate

News and Trends 26 Oct 2022

Recursion announces $150M private placement

U.S. biotech Recursion Pharmaceuticals has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million shares of its Class A common stock in a private placement. It was led by Kinnevik AB, with participation by Baillie Gifford, Mubadala Investment Company, Laurion Capital Management, Invus, and Platinum Asset Management. The […]

October 26, 2022 - 2 minutesmins - By Jim Cornall

Mike Nally Generate Biomedicines ai drug discovery

Interview 12 Oct 2022

Boosting pharma’s falling productivity with AI in drug discovery

The pharmaceutical industry is struggling with mounting costs of drug development. Generate Biomedicines’ CEO, Michael Nally, outlines the firm’s mission to tackle the trend by making drug discovery scalable. Over the decades, the pharma and biopharma industry has suffered a growing stagnation in productivity. According to a report from University College London in 2018, for […]

October 12, 2022 - 5 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Drug discovery

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

How cardioids can usher in the next generation of drug discovery

Sensorium closes $30M deal to advance drug discovery engine

Google and Meta AI could boost cancer research and drug discovery

Optibrium and Lhasa Limited study published on predictive modelling for enzymes

First to market doesn’t guarantee success

Drug discovery company signs exclusive license to use university’s technology

PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets

AI and biobanks could open the way to longevity treatments

Partnership between Paradigm4 and Alnylam accelerates drug target discovery

Recursion announces $150M private placement

Boosting pharma’s falling productivity with AI in drug discovery

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!